(Q46307739)

21 December 2017

title

Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage (English)

1 reference

21 December 2017

enzyme replacement therapy

main subject

0 references

1 reference

R Y Wang

1

1 reference

21 December 2017

J T Abe

series ordinal

2

1 reference

21 December 2017

A H Cohen

series ordinal

3

1 reference

21 December 2017

W R Wilcox

series ordinal

4

1 reference

21 December 2017

publication date

21 October 2008

1 reference

21 December 2017

Journal of Inherited Metabolic Disease

published in

1 reference

21 December 2017

volume

31 Suppl 2

1 reference

21 December 2017

page(s)

S369-74

1 reference

21 December 2017

https://scigraph.springernature.com/pub.10.1007/s10545-008-0930-x

exact match

0 references

cites work

Pulmonary pathology in Gaucher's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Pulmonary involvement in Fabry's disease: a reappraisal follow-up of a San Diego kindred and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Cardiopulmonary exercise testing in Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Induced sputum examination: diagnosis of pulmonary involvement in Fabry's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Pulmonary function abnormalities in type I Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Natural history of the respiratory involvement in Anderson-Fabry disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Standardisation of spirometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-008-0930-X

Severe endothelial dysfunction in the aorta of a mouse model of Fabry disease; partial prevention by N-butyldeoxynojirimycin treatment

21 January 2018

1 reference

12 December 2020

Pulmonary vasculature in Fabry's disease

1 reference

12 December 2020

Pulmonary involvement by Niemann-Pick disease. A report of six cases

1 reference

12 December 2020

Pulmonary involvement in Fabry's disease

1 reference

12 December 2020

Chronic airflow obstruction in Fabry's disease

1 reference

12 December 2020

Pulmonary involvement in Fabry disease

1 reference

12 December 2020

Infantile GM1-gangliosidosis with marked manifestation of lungs

1 reference

12 December 2020

Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease

1 reference

12 December 2020

Fabry's disease. A correlative clinical, morphologic, and biochemical study

1 reference

12 December 2020

The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease

1 reference

12 December 2020

Structural and functional changes in peripheral vasculature of Fabry patients

1 reference

12 December 2020

Pulmonary manifestations of Fabry disease and positive response to enzyme replacement therapy

1 reference

12 December 2020

10.1007/S10545-008-0930-X

Identifiers

DOI

1 reference

21 December 2017

PubMed ID

18937048

1 reference

21 December 2017